Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA123892
Max Phase: Preclinical
Molecular Formula: C14H15N5OS
Molecular Weight: 301.38
Molecule Type: Small molecule
Associated Items:
ID: ALA123892
Max Phase: Preclinical
Molecular Formula: C14H15N5OS
Molecular Weight: 301.38
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1ccc(Sc2[nH]c3nc(N)nc(N)c3c2C)cc1
Standard InChI: InChI=1S/C14H15N5OS/c1-7-10-11(15)17-14(16)19-12(10)18-13(7)21-9-5-3-8(20-2)4-6-9/h3-6H,1-2H3,(H5,15,16,17,18,19)
Standard InChI Key: MEEJAHCUJQZESD-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 301.38 | Molecular Weight (Monoisotopic): 301.0997 | AlogP: 2.59 | #Rotatable Bonds: 3 |
Polar Surface Area: 102.84 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.36 | CX Basic pKa: 8.36 | CX LogP: 2.77 | CX LogD: 1.79 |
Aromatic Rings: 3 | Heavy Atoms: 21 | QED Weighted: 0.69 | Np Likeness Score: -0.72 |
1. Gangjee A, Lin X, Queener SF.. (2004) Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors., 47 (14): [PMID:15214795] [10.1021/jm0306327] |
2. Gangjee A, Zeng Y, Talreja T, McGuire JJ, Kisliuk RL, Queener SF.. (2007) Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates., 50 (13): [PMID:17552508] [10.1021/jm070165j] |
3. Gangjee A, Lin X, Biondo LR, Queener SF.. (2010) CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified cross-validated r(2)-guided region selection (q(2)-GRS) routine and its initial application., 18 (4): [PMID:20117005] [10.1016/j.bmc.2009.12.066] |
4. Shah K, Lin X, Queener SF, Cody V, Pace J, Gangjee A.. (2018) Targeting species specific amino acid residues: Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors and potential anti-opportunistic infection agents., 26 (9): [PMID:29691153] [10.1016/j.bmc.2018.04.032] |
Source(1):